MapLight Reports Q3 2026 Net Loss of $51.6M, Advances ZEPHYR-2 Phase 3 Trial Planning
MapLight Therapeutics reported Q3 2026 net loss of $51.6 million versus $29.4 million in Q3 2025, with R&D expenses increasing to $44.2 million from $27.1 million year-over-year due to clinical trial advancement and increased employee-related costs including stock-based compensation. The company ended Q3 2026 with $463.4 million in cash, cash equivalents and investments, expected to fund operations through 2028. The company initiated start-up activities for ZEPHYR-2, its planned Phase 3 trial of ML-007C-MA in sc...
Key takeaways
Net loss widened to $51.6 million in Q3 2026 from $29.4 million in Q3 2025, driven by increased R&D and G&A spending
R&D expenses increased 63% year-over-year to $44.2 million due to clinical trial advancement and higher stock-based compensation ($5.8 million increase)
Cash position of $463.4 million as of September 30, 2026 expected to fund operations through 2028
ZEPHYR-2 Phase 3 trial initiation underway for ML-007C-MA in schizophrenia with topline results expected in 2H 2027
Phase 2 VISTA trial in Alzheimer's disease psychosis enrollment ongoing with topline results expected in 2028
ML-007C-MA received FDA Fast Track designation in December 2025 for ADP treatment
Company completed $150 million private placement in August 2026 to support clinical development
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow MPLT in real time
Get material earnings, filing, IR, and earnings-call alerts by email.